Description

Enhertu (trastuzumab deruxtecan)

Targeted therapy for HER2-expressing cancers

Hero Section

Transforming outcomes in HER2-positive and HER2-low cancers
Enhertu is a HER2-directed antibody-drug conjugate designed to deliver targeted chemotherapy inside cancer cells, helping treat certain advanced solid tumors.

Learn more about how Enhertu works →

---

About Enhertu

Enhertu is a prescription cancer therapy known as an antibody-drug conjugate (ADC). It combines:

• A HER2-targeting monoclonal antibody
• A topoisomerase I inhibitor chemotherapy payload
• A cleavable linker that releases the drug inside cancer cells

This design helps deliver treatment more precisely to HER2-expressing tumor cells while minimizing exposure to healthy tissues.

---

How Enhertu Works

Enhertu is designed to:

1. Bind to HER2 receptors on cancer cells
2. Enter the cancer cell through receptor-mediated internalization
3. Release chemotherapy inside the tumor cell
4. Induce DNA damage, leading to cancer cell death
5. Provide a “bystander effect”, helping target nearby tumor cells as well

---

Approved Uses*

Enhertu is used in certain patients with:

• HER2-positive breast cancer
• HER2-low breast cancer
• HER2-mutant or HER2-expressing non-small cell lung cancer
• HER2-positive gastric or gastroesophageal cancers

*Indications may vary depending on country and regulatory approval.

---

Who It May Be For

Enhertu may be considered for adult patients who:

• Have metastatic or unresectable HER2-expressing cancer
• Have previously received other anti-HER2 therapies
• Require systemic treatment as recommended by an oncology specialist

---

Administration

• Given as an intravenous (IV) infusion
• Administered in a hospital or clinical setting
• Dosing and schedule are determined by a healthcare provider

---

Safety Information

Like all cancer therapies, Enhertu may cause side effects. Commonly reported ones include:

• Nausea and vomiting
• Fatigue
• Hair loss
• Low blood counts
• Decreased appetite

Serious risks may include:

• Interstitial lung disease (ILD)/pneumonitis
• Cardiac effects
• Severe bone marrow suppression

Patients should be closely monitored by their healthcare team during treatment.

---

Important Notice

Enhertu is a prescription-only oncology medicine. It should only be used under the supervision of a qualified healthcare professional. Individual results and eligibility may vary.

This page is intended for educational and informational purposes only and does not replace medical advice.

---

Talk to a Specialist

If you or someone you know has been diagnosed with a HER2-expressing cancer, speak with an oncologist to understand whether Enhertu may be appropriate as part of a treatment plan.

---